Symbols / CDT
CDT Chart
About
CDT Equity Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It has strategic services agreement with formulation development CDMO Agility Life Sciences to develop new solid oral-dosage form products. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.58M |
| Enterprise Value | -844.41K | Income | -20.30M | Sales | — |
| Book/sh | 3.35 | Cash/sh | 2.35 | Dividend Yield | — |
| Payout | 0.00% | Employees | 6 | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | — | P/B | 0.20 | P/C | — |
| EV/EBITDA | 0.05 | EV/Sales | — | Quick Ratio | 0.99 |
| Current Ratio | 1.66 | Debt/Eq | 43.83 | LT Debt/Eq | — |
| EPS (ttm) | -179.34 | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-12 15:00 | ROA | -206.95% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 2.30M |
| Shs Float | 1.29M | Short Float | 12.18% | Short Ratio | 0.90 |
| Short Interest | — | 52W High | 168.00 | 52W Low | 0.61 |
| Beta | 1.77 | Avg Volume | 781.00K | Volume | 297.60K |
| Target Price | — | Recom | None | Prev Close | $0.72 |
| Price | $0.69 | Change | -4.25% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.69
Latest analyst target
3. DCF / Fair value
$-129.25
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.69
Low
—
High
—
Mean
—
News
RSS: Latest CDT news- CDT Equity to Acquire 20% of Sarborg in Stock, Pre-Funded Warrants and $8 Million Cash - TradingView ue, 24 Feb 2026 22
- CDT’s Sarborg bet: 4,500 agrochemical, 1,600 bacterial AI signatures - Stock Titan ue, 24 Feb 2026 13
- CDT Equity Inc. Acknowledges Sarborg Limited's Expansion of AI Signature Agent Platform into Bacteria and Agrochemicals - Quiver Quantitative ue, 24 Feb 2026 13
- CDT Equity Inc (CDT) Stock Price, Quote, News & History - Benzinga Sat, 21 Feb 2026 00
- CDT Equity stock tumbles after $115M Sarborg stake deal - Investing.com Fri, 20 Feb 2026 15
- Conduit Pharmaceuticals Expands Stake Using Equity-Funded Acquisition Strategy - TipRanks ue, 24 Feb 2026 23
- CDT Stock Dips as Financial Challenges Mount Amid Market Shifts - timothysykes.com Fri, 20 Feb 2026 14
- CDT Equity Notes Sarborg Expansion into Bacteria and Agrochemicals - ChartMill ue, 24 Feb 2026 13
- CDT Equity To Buy 20% Stake In Sarborg To Expand AI Offerings - Nasdaq Fri, 20 Feb 2026 14
- CDT’s $115M AI ‘signature’ bet reaches far beyond pharmaceuticals - Stock Titan Fri, 20 Feb 2026 13
- CDT Equity to Acquire 20% Stake in AI Firm Sarborg for $115 Million - marketscreener.com Fri, 20 Feb 2026 14
- CDT Environmental Technology Announces Private Placement of Common Stock - Yahoo Finance ue, 06 Jan 2026 08
- CDT Equity notes Sarborg expansion into bacteria, agrochemicals - TipRanks ue, 24 Feb 2026 14
- CDT Equity acquires 20% stake in Sarborg for $115 million - Investing.com Fri, 20 Feb 2026 13
- CDT Acquires Strategic Stake in Sarborg to Transform its AI-Driven Asset Strategy - ChartMill Fri, 20 Feb 2026 13
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 224800 | 402392.0 | — | Stock Award(Grant) at price 1.79 per share. | REGAN ANDREW J. | Chief Executive Officer | — | 2025-12-08 00:00:00 | I |
| 1 | 480000 | nan | — | — | BLIGH JAMES | Chief Financial Officer | — | 2025-09-19 00:00:00 | D |
| 2 | 1120000 | 768656.0 | — | Stock Award(Grant) at price 0.69 per share. | REGAN ANDREW J. | Chief Executive Officer | — | 2025-09-19 00:00:00 | D |
| 3 | 35000 | nan | — | — | LEWIS-HALL FREDA C | Director | — | 2025-08-12 00:00:00 | D |
| 4 | 35000 | nan | — | — | FARLEY CHELE CHIAVACCI | Director | — | 2025-08-12 00:00:00 | D |
| 5 | 35000 | nan | — | — | FRY SIMON JEREMY | Director | — | 2025-08-12 00:00:00 | D |
| 6 | 154799 | 500001.0 | — | Stock Award(Grant) at price 3.23 per share. | REGAN ANDREW J. | Chief Executive Officer | — | 2025-06-03 00:00:00 | I |
| 7 | 115194 | 100000.0 | — | Stock Award(Grant) at price 0.87 per share. | CHARLES FAITH L. | Director | — | 2025-04-16 00:00:00 | D |
| 8 | 47612 | 42375.0 | — | Stock Award(Grant) at price 0.89 per share. | LEWIS-HALL FREDA C | Director | — | 2025-03-28 00:00:00 | D |
| 9 | 46629 | 41500.0 | — | Stock Award(Grant) at price 0.89 per share. | CHARLES FAITH L. | Director | — | 2025-03-28 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 1.45M | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.21 | 0.00 | 0.00 |
| NormalizedEBITDA | -15.35M | -3.85M | -3.42M | -2.76M |
| TotalUnusualItems | -500.00K | 6.90M | -1.46M | -411.00K |
| TotalUnusualItemsExcludingGoodwill | -500.00K | 6.90M | -1.46M | -411.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -17.80M | -535.00K | -4.89M | -3.66M |
| ReconciledDepreciation | 457.00K | 0.00 | ||
| EBITDA | -15.85M | 3.05M | -4.89M | -3.17M |
| EBIT | -16.31M | 3.05M | -4.89M | -3.17M |
| NetInterestIncome | -1.49M | -196.00K | 0.00 | |
| InterestExpense | 1.51M | 211.00K | 0.00 | |
| InterestIncome | 13.00K | 15.00K | 0.00 | |
| NormalizedIncome | -17.30M | -5.99M | -3.42M | -3.25M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -17.80M | -535.00K | -4.89M | -3.66M |
| TotalExpenses | 15.12M | 5.26M | 3.16M | 3.17M |
| TotalOperatingIncomeAsReported | -15.42M | -5.26M | -3.16M | -3.17M |
| DilutedAverageShares | 57.81K | 45.26K | 48.28K | 48.28K |
| BasicAverageShares | 57.81K | 44.65K | 48.28K | 48.28K |
| DilutedEPS | -307.95 | -1.07K | -101.23 | -75.75 |
| BasicEPS | -307.95 | -94.80 | -101.23 | -75.75 |
| DilutedNIAvailtoComStockholders | -17.80M | -6.06M | -4.89M | -3.66M |
| AverageDilutionEarnings | 0.00 | -5.52M | ||
| NetIncomeCommonStockholders | -17.80M | -535.00K | -4.89M | -3.66M |
| NetIncome | -17.80M | -535.00K | -4.89M | -3.66M |
| NetIncomeIncludingNoncontrollingInterests | -17.81M | 2.84M | -4.89M | -3.66M |
| NetIncomeContinuousOperations | -17.81M | 2.84M | -4.89M | -3.66M |
| PretaxIncome | -17.81M | 2.84M | -4.89M | -3.66M |
| OtherIncomeExpense | -1.20M | 8.30M | -1.73M | -484.00K |
| OtherNonOperatingIncomeExpenses | -700.00K | 1.40M | -265.00K | -73.00K |
| GainOnSaleOfSecurity | -500.00K | 6.90M | -1.46M | -411.00K |
| NetNonOperatingInterestIncomeExpense | -1.49M | -196.00K | 0.00 | |
| InterestExpenseNonOperating | 1.51M | 211.00K | 0.00 | |
| InterestIncomeNonOperating | 13.00K | 15.00K | 0.00 | |
| OperatingIncome | -15.12M | -5.26M | -3.16M | -3.17M |
| OperatingExpense | 15.12M | 5.26M | 3.16M | 3.17M |
| OtherTaxes | -300.00K | |||
| ResearchAndDevelopment | 3.38M | 90.00K | 111.00K | 283.00K |
| SellingGeneralAndAdministration | 12.04M | 5.17M | 3.05M | 2.89M |
| GeneralAndAdministrativeExpense | 12.04M | 5.17M | 3.05M | 2.89M |
| OtherGandA | 12.04M | 5.17M | 3.05M | 2.89M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 92.32K | 49.22K | 48.28K | 48.28K |
| ShareIssued | 92.32K | 49.22K | 48.28K | 48.28K |
| NetDebt | 6.68M | 2.01M | 749.00K | |
| TotalDebt | 7.46M | 985.00K | 2.01M | 749.00K |
| TangibleBookValue | -6.79M | -457.00K | -10.09M | -5.94M |
| InvestedCapital | 438.00K | 528.00K | -8.08M | -5.19M |
| WorkingCapital | -8.03M | 3.93M | -4.18M | |
| NetTangibleAssets | -6.79M | -457.00K | -10.09M | -5.94M |
| CapitalLeaseObligations | 226.00K | 0.00 | ||
| CommonStockEquity | -6.79M | -457.00K | -10.09M | -5.94M |
| TotalCapitalization | -6.79M | -457.00K | -8.25M | -5.19M |
| TotalEquityGrossMinorityInterest | -6.79M | -457.00K | -10.09M | -5.94M |
| StockholdersEquity | -6.79M | -457.00K | -10.09M | -5.94M |
| GainsLossesNotAffectingRetainedEarnings | 414.00K | 411.00K | 675.00K | -65.00K |
| OtherEquityAdjustments | 414.00K | 411.00K | 675.00K | -65.00K |
| RetainedEarnings | -29.10M | -11.30M | -10.77M | -5.88M |
| AdditionalPaidInCapital | 21.88M | 10.42M | 0.00 | |
| CapitalStock | 14.00K | 7.00K | 6.00K | 0.00 |
| CommonStock | 14.00K | 7.00K | 6.00K | 0.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 | |
| TotalLiabilitiesNetMinorityInterest | 10.99M | 7.68M | 10.09M | 5.94M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 245.00K | 5.88M | 5.92M | 3.71M |
| DerivativeProductLiabilities | 138.00K | 142.00K | 0.00 | |
| TradeandOtherPayablesNonCurrent | 0.00 | 5.74M | 0.00 | |
| NonCurrentDeferredLiabilities | 0.00 | 4.08M | 2.96M | |
| NonCurrentDeferredRevenue | 0.00 | 4.08M | 2.96M | |
| LongTermDebtAndCapitalLeaseObligation | 107.00K | 0.00 | 1.83M | 749.00K |
| LongTermCapitalLeaseObligation | 107.00K | 0.00 | ||
| LongTermDebt | 1.83M | 749.00K | ||
| CurrentLiabilities | 10.74M | 1.80M | 4.18M | 2.23M |
| OtherCurrentLiabilities | 1.42M | 6.00K | ||
| CurrentDebtAndCapitalLeaseObligation | 7.35M | 985.00K | 175.00K | |
| CurrentCapitalLeaseObligation | 119.00K | 0.00 | ||
| CurrentDebt | 7.23M | 985.00K | 175.00K | |
| OtherCurrentBorrowings | 6.66M | 800.00K | 175.00K | |
| CurrentNotesPayable | 575.00K | 185.00K | ||
| PayablesAndAccruedExpenses | 3.39M | 816.00K | 2.58M | 2.23M |
| CurrentAccruedExpenses | 1.96M | 601.00K | 2.58M | 2.23M |
| Payables | 1.43M | 215.00K | ||
| AccountsPayable | 1.43M | 215.00K | 0.00 | |
| TotalAssets | 4.19M | 7.22M | 5.00K | 0.00 |
| TotalNonCurrentAssets | 1.48M | 1.49M | 5.00K | 0.00 |
| OtherNonCurrentAssets | 1.18M | 1.49M | ||
| GoodwillAndOtherIntangibleAssets | 0.00 | 5.00K | 0.00 | |
| OtherIntangibleAssets | 5.00K | |||
| NetPPE | 303.00K | 0.00 | ||
| GrossPPE | 303.00K | 0.00 | ||
| OtherProperties | 303.00K | |||
| CurrentAssets | 2.71M | 5.73M | 0.00 | |
| PrepaidAssets | 1.67M | 1.50M | 0.00 | |
| Receivables | 489.00K | 0.00 | ||
| OtherReceivables | 489.00K | |||
| CashCashEquivalentsAndShortTermInvestments | 554.00K | 4.23M | 0.00 | |
| CashAndCashEquivalents | 554.00K | 4.23M | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -9.73M | -7.72M | -2.27M | -2.15M |
| RepaymentOfDebt | -776.00K | 0.00 | ||
| IssuanceOfDebt | 3.23M | 2.29M | 1.11M | 688.00K |
| IssuanceOfCapitalStock | 3.33M | 0.00 | 1.34M | 1.21M |
| CapitalExpenditure | -51.00K | |||
| InterestPaidSupplementalData | 80.00K | 124.00K | 0.00 | |
| EndCashPosition | 554.00K | 4.23M | 0.00 | 0.00 |
| BeginningCashPosition | 4.23M | 0.00 | 0.00 | 252.00K |
| EffectOfExchangeRateChanges | -16.00K | 299.00K | 1.00K | 1.00K |
| ChangesInCash | -3.66M | 3.93M | -1.00K | -253.00K |
| FinancingCashFlow | 6.07M | 10.93M | 2.45M | 1.90M |
| CashFlowFromContinuingFinancingActivities | 6.07M | 10.93M | 2.45M | 1.90M |
| NetOtherFinancingCharges | 8.64M | |||
| ProceedsFromStockOptionExercised | 289.00K | 0.00 | ||
| NetCommonStockIssuance | 3.33M | 0.00 | 1.34M | 1.21M |
| CommonStockIssuance | 3.33M | 0.00 | 1.34M | 1.21M |
| NetIssuancePaymentsOfDebt | 2.45M | 2.29M | 1.11M | 688.00K |
| NetShortTermDebtIssuance | 2.45M | 2.29M | ||
| ShortTermDebtPayments | -776.00K | 0.00 | ||
| ShortTermDebtIssuance | 3.23M | 2.29M | ||
| NetLongTermDebtIssuance | 2.29M | 1.11M | 688.00K | |
| LongTermDebtIssuance | 2.29M | 1.11M | 688.00K | |
| InvestingCashFlow | -43.00K | 725.00K | -183.00K | 0.00 |
| CashFlowFromContinuingInvestingActivities | -43.00K | 725.00K | -183.00K | 0.00 |
| NetOtherInvestingChanges | 228.00K | -331.00K | ||
| NetInvestmentPurchaseAndSale | 8.00K | 497.00K | 148.00K | 0.00 |
| SaleOfInvestment | 498.00K | 497.00K | 148.00K | 0.00 |
| PurchaseOfInvestment | -490.00K | 0.00 | ||
| NetPPEPurchaseAndSale | -51.00K | 0.00 | ||
| PurchaseOfPPE | -51.00K | 0.00 | ||
| OperatingCashFlow | -9.68M | -7.72M | -2.27M | -2.15M |
| CashFlowFromContinuingOperatingActivities | -9.68M | -7.72M | -2.27M | -2.15M |
| ChangeInWorkingCapital | -142.00K | -2.52M | 596.00K | 1.36M |
| ChangeInOtherWorkingCapital | 331.00K | |||
| ChangeInOtherCurrentLiabilities | -124.00K | 0.00 | ||
| ChangeInOtherCurrentAssets | 0.00 | 5.00K | -5.00K | 0.00 |
| ChangeInPayablesAndAccruedExpense | 2.25M | -1.53M | 601.00K | 1.36M |
| ChangeInAccruedExpense | 1.03M | -1.75M | 601.00K | 1.36M |
| ChangeInPayable | 1.23M | 215.00K | ||
| ChangeInAccountPayable | 1.23M | 215.00K | 0.00 | |
| ChangeInPrepaidAssets | -2.27M | -990.00K | 0.00 | |
| OtherNonCashItems | 2.97M | 992.00K | 265.00K | |
| StockBasedCompensation | 1.63M | 199.00K | 0.00 | |
| ProvisionandWriteOffofAssets | 0.00 | -240.00K | 331.00K | |
| DepreciationAmortizationDepletion | 457.00K | 0.00 | ||
| DepreciationAndAmortization | 457.00K | 0.00 | ||
| AmortizationCashFlow | 447.00K | 0.00 | ||
| AmortizationOfIntangibles | 447.00K | 0.00 | ||
| Depreciation | 10.00K | 0.00 | ||
| OperatingGainsLosses | 3.20M | -5.62M | 1.43M | 149.00K |
| GainLossOnInvestmentSecurities | 2.48M | -5.60M | 1.43M | 149.00K |
| NetForeignCurrencyExchangeGainLoss | 13.00K | -39.00K | 0.00 | |
| NetIncomeFromContinuingOperations | -17.80M | -535.00K | -4.89M | -3.66M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CDT
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|